unresponsiveness colon cancer brafv600e inhibition feedback activation egfr
inhibition brafv600e oncoprotein small-molecule drug plx4032 vemurafenib highly effective treatment melanoma however colon cancer patients harbouring braf v600e oncogenic lesion poor prognosis show limited response drug- investigate cause limited therapeutic effect plx4032 braf v600e mutant colon tumours performed rna-interference-based genetic screen human cells search kinases whose knockdown synergizes brafv600e inhibition report blockade epidermal growth factor receptor egfr shows strong synergy brafv600e inhibition find multiple braf v600e mutant colon cancers inhibition egfr antibody drug cetuximab small-molecule drugs gefitinib erlotinib strongly synergistic brafv600e inhibition vitro vivo mechanistically find brafv600e inhibition causes rapid feedback activation egfr supports continued proliferation presence brafv600e inhibition melanoma cells express low levels egfr therefore subject feedback activation consistent find ectopic expression egfr melanoma cells sufficient cause resistance plx4032 data suggest brafv600e mutant colon cancers approximately % colon cancers currently targeted treatment options available might benefit combination therapy consisting braf egfr inhibitors
